LYL273 for Patients With Relapsed or Refractory mCRC

Part of paid clinical trials in Duarte, California.

Sponsor
Lyell Immunopharma, Inc.
Study ID
NCT05319314
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • LYL273 — DRUG
    Single infusion of Chimeric Antigen Receptor (CAR) transduced autologous T cells administered intravenously (i.v.)

Study Details

This is a Phase 1/2 open-label, multicenter study evaluating the safety and efficacy of LYL273 in participants with relapsed or refractory metastatic colorectal cancer.

Key Dates

Start date
Aug 1, 2022
Status verified
Jun 2026
Primary completion
Jun 30, 2028
Completion
Jun 30, 2032

Study Design

Enrollment
155 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: LYL273
    Single infusion of LYL273 at the dose assigned to an individual participant. All participants will receive the same investigational therapy with the dose administered dependent upon the dose level they are assigned to in a sequential manner.

Primary Outcome Measure

Phase 1: Incidence of adverse events (AEs) defined as dose-limiting toxicities (DLTs) during 3+3 dose escalation study [ Time Frame: Infusion (Day 0) to Day 28 ]

Locations (4)

FacilityCityStateZIPSite coordinators
City of Hope Comprehensive Cancer CenterDuarteCalifornia91010
Jessica Mathias
[email protected]
626-218-4088
Kimberly Le
[email protected]
626-218-2997
University of California San Francisco Medical CenterSan FranciscoCalifornia94143
UCSF Team
[email protected]
415-818-4579
University of Colorado Hospital - Anschutz Cancer PavilionAuroraColorado80045
Meredith Waring
[email protected]
303-724-9840
Alexander Pung
[email protected]
303-724-9632
Dana-Farber Cancer InstituteBostonMassachusetts02215-5418
Jamie Dela Cruz
[email protected]
857-215-2833

Find similar trials in Duarte, CA

By condition
Colorectal cancer
By specialty
OncologyGI oncology
By research site
City of Hope Comprehensive Cancer Center· Duarte, CAUniversity of California San Francisco Medical Center· San Francisco, CAUniversity of Colorado Hospital - Anschutz Cancer Pavilion· Aurora, CODana-Farber Cancer Institute· Boston, MA

Related Studies